Search results for "MACRO"

showing 10 items of 3471 documents

Modulation of adipokines and cytokines in gestational diabetes and macrosomia.

2006

Abstract Context/Objective: Not much is known about the implication of adipokines and different cytokines in gestational diabetes mellitus (GDM) and macrosomia. The purpose of this study was to assess the profile of these hormones and cytokines in macrosomic babies, born to gestational diabetic women. Design/Subjects: A total of 59 women (age, 19–42 yr) suffering from GDM with their macrosomic babies (4.35 ± 0.06 kg) and 60 healthy age-matched pregnant women and their newborns (3.22 ± 0.08 kg) were selected. Methods: Serum adipokines (adiponectin and leptin) were quantified using an obesity-related multiple ELISA microarray kit. The concentrations of serum cytokines were determined by ELISA…

AdultBlood GlucoseLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismClinical BiochemistryAdipokineBiochemistryProinflammatory cytokineFetal MacrosomiaInterferon-gammaEndocrinologyAldesleukinPregnancyInternal medicineDiabetes mellitusFetal macrosomiaMedicineHumansInsulinAdiponectinbusiness.industryInterleukin-6Tumor Necrosis Factor-alphaLeptinBiochemistry (medical)Infant Newbornmedicine.diseaseLipidsGestational diabetesDiabetes GestationalEndocrinologyCytokinesInterleukin-2FemaleAdiponectinInterleukin-4businessThe Journal of clinical endocrinology and metabolism
researchProduct

Glucose control in the older patient: from intensive, to effective and safe.

2009

Older adults represent an extensive proportion of Type 2 diabetic patients. Managing diabetes in this population is challenging, because complex comorbidity and disability often mean that guidelines are not suitable on an individual basis. Recent evidence has raised animated discussion of the possibility that intensive glucose control may cause more harm than benefit, especially in older adults. The benefit of glycemic control on microvascular diabetic complications has been consistently demonstrated, but the evidence of benefit on macrovascular disease is not uniform in all studies. Glycemic control appears to prevent the development of cardiovascular events, but is less helpful in seconda…

AdultBlood GlucoseMaleAgingmedicine.medical_specialtyPopulationType 2 diabetesHypoglycemiaDiabetes ComplicationsDiabetes mellitusNeoplasmsmedicineDementiaHumansHypoglycemic AgentsInsulinIntensive care medicineeducationMacrovascular diseaseGlycemicAgedRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryAge FactorsMiddle Agedmedicine.diseaseComorbidityHypoglycemiaDiabetes Mellitus Type 2Accidental FallsDementiaFemaleGeriatrics and GerontologybusinessAging clinical and experimental research
researchProduct

Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors.

2007

Increased C3 has been related to body mass index (BMI) and insulin resistance, although there are not sufficient studies in subjects with morbid obesity. The purpose of this study was to evaluate the levels of C3 as a function of the BMI in subjects of both sexes, with severe, morbid and extreme obesity, and their possible relationship to insulin resistance or associated diseases such as diabetes, hypertension and dyslipidemia.The study included a total of 316 patients (110 men and 206 women) with severe obesity (17.1%), morbid obesity (54.4%) and extreme obesity (28.4%), with an average BMI of 46.70+/-7.37 kg/m2.The glucose and insulin levels were determined baseline, and 2 h after a 75 g …

AdultBlood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedicine (miscellaneous)Blood Pressuremacromolecular substancesBody Mass IndexInsulin resistanceRisk FactorsInternal medicineEpidemiologymedicineHyperinsulinemiaHumansInsulinObesityRisk factorPancreatic hormoneDyslipidemiasNutrition and DieteticsVascular diseasebusiness.industryInsulinComplement C3medicine.diseaseObesity MorbidEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesHypertensionFemaleInsulin ResistancebusinessHyperinsulinismInternational journal of obesity (2005)
researchProduct

Implication of lipids in macrosomia of diabetic pregnancy: can n-3 polyunsaturated fatty acids exert beneficial effects?

2003

Macrosomia or fetal obesity is a frequent complication of pregnancy in diabetes mellitus. Several alterations observed in carbohydrate and lipid metabolism in macrosomic infants of diabetic mothers are thought to be a consequence of maternal hyperglycaemia leading to fetal hyperinsulinaemia. Macrosomic infants of diabetic mothers are prone to the development of glucose intolerance, obesity and diabetes during childhood and adulthood. Furthermore, increasing evidence is accumulating regarding the importance of n-3 polyunsaturated fatty acids (PUFAs) in the reduction of plasma lipids and hyperglycaemia. In this review article, we shed light on the abnormalities in lipid metabolism in macrosom…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesLipoproteinsPregnancy in DiabeticsFetal MacrosomiaPregnancyDiabetes mellitusInternal medicineFatty Acids Omega-3Diabetes MellitusmedicineAnimalsHumansObesitychemistry.chemical_classificationPregnancyFetusbusiness.industryMetabolic disorderInfant NewbornLipid metabolismGeneral MedicineLipid Metabolismmedicine.diseaseObesityGestational diabetesEndocrinologychemistryFemaleInsulin ResistancebusinessPolyunsaturated fatty acidClinical Science
researchProduct

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

Advanced Platelet-Rich Fibrin: A New Concept for Cell-Based Tissue Engineering by Means of Inflammatory Cells

2014

Choukroun's platelet-rich fibrin (PRF) is obtained from blood without adding anticoagulants. In this study, protocols for standard platelet-rich fibrin (S-PRF) (2700 rpm, 12 minutes) and advanced platelet-rich fibrin (A-PRF) (1500 rpm, 14 minutes) were compared to establish by histological cell detection and histomorphometrical measurement of cell distribution the effects of the centrifugal force (speed and time) on the distribution of cells relevant for wound healing and tissue regeneration. Immunohistochemistry for monocytes, T and B -lymphocytes, neutrophilic granulocytes, CD34-positive stem cells, and platelets was performed on clots produced from four different human donors. Platelets …

AdultBlood PlateletsPathologymedicine.medical_specialtyBone RegenerationErythrocytesTime FactorsAdolescentNeutrophilsT-LymphocytesAntigens CD34CentrifugationInflammationCell SeparationMonocytesFibrinYoung AdultTissue engineeringmedicineHumansRegenerationPlateletB-LymphocytesFibrinTissue Engineeringbiologybusiness.industryMacrophagesStem CellsCell DifferentiationMiddle AgedImmunohistochemistrydigestive system diseasesPlatelet-rich fibrinBlood Buffy Coatbiology.proteinOral Surgerymedicine.symptombusinessCell basedJournal of Oral Implantology
researchProduct

Expression of host defense scavenger receptors in spondylarthropathy

2001

Objective Reactive arthritis (ReA) is postulated to be caused by a defective host defense against gram-negative bacteria. HLA–B27 could play a role in this process, but does not account for the many HLA–B27 negative patients. The objective of this study was to test the expression of 3 macrophage scavenger receptors (SRs) that are responsible for innate immunity against gram-negative bacteria: SR class A type I (SR-AI), SR-AII, and the macrophage receptor with collagenous structure (MARCO). We postulate that defects in such receptors might also contribute to the host risk factors that increase the predisposition to ReA and perhaps other subtypes of spondylarthropathy (SpA). Methods Periphera…

AdultCD36 AntigensMalemusculoskeletal diseasesCellular immunityAdolescentInflammatory arthritisImmunologyPeripheral blood mononuclear cellArthritis ReactiveImmune systemRheumatologyProhibitinsSynovial FluidmedicineImmunology and AllergySynovial fluidHumansPharmacology (medical)Spondylitis AnkylosingRNA MessengerScavenger receptorReceptors ImmunologicDNA PrimersReceptors LipoproteinReceptors Scavengerbusiness.industryReverse Transcriptase Polymerase Chain ReactionMacrophagesSynovial MembraneMembrane ProteinsScavenger Receptors Class AMiddle AgedScavenger Receptors Class Bmedicine.diseaseMacrophage receptor with collagenous structuremedicine.anatomical_structureImmunologySalmonella InfectionsLeukocytes MononuclearFemaleSynovial membranebusinessArthritis and rheumatism
researchProduct

Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug-resistant epilepsy

2020

OBJECTIVE: Adult drug-resistant epilepsy (DRE) is associated with significant morbidity. Infiltration of immune cells is observed in DRE epileptic foci; however, the relation between DRE and the peripheral immune cell compartment remains only partially understood. We aimed to investigate differences in immune cell populations, cytokines, and neurodegenerative biomarkers in the peripheral blood of subjects with epilepsy versus healthy controls, and in DRE compared to well-controlled epilepsy (WCE). METHODS: Peripheral blood mononuclear cells and serum from >120 age- and sex-matched adults suffering from focal onset epilepsy and controls were analyzed by multipanel flow cytometry, multiplex i…

AdultCD4-Positive T-LymphocytesMale0301 basic medicineDrug Resistant Epilepsymedicine.medical_treatmenturologic and male genital diseasesPeripheral blood mononuclear cellProinflammatory cytokineInterferon-gammaYoung Adult03 medical and health sciencesEpilepsyTh2 Cells0302 clinical medicineImmune systemNeurofilament ProteinsmedicineHumansImmunoassayInflammationEpilepsyTumor Necrosis Factor-alphabusiness.industryInterleukinsInterleukin-17NeurotoxicityGranulocyte-Macrophage Colony-Stimulating FactorInterleukinMiddle AgedFlow Cytometrymedicine.diseaseSingle Molecule ImagingCD4 Lymphocyte CountInterleukin-10030104 developmental biologyCytokineNeurologyCase-Control StudiesImmunologyCytokinesTh17 CellsFemaleTumor necrosis factor alphaInterleukin-4Neurology (clinical)business030217 neurology & neurosurgery
researchProduct

Distribution of a special subset of keratinocytes characterized by the expression of cytokeratin 9 in adult and fetal human epidermis of various body…

1987

Biochemical analyses have previously shown that palmar and plantar epidermis, unlike the epidermis of other body sites, contain cytokeratin 9 (Mr 64,000), an unusually large acidic (type I) cytokeratin. Guinea-pig antibodies that specifically and selectively react with bovine and human cytokeratin 9 were used for the immunocytochemical identification of cytokeratin 9 in adult and fetal human epidermis from various body sites. In the epidermis of palms and soles, antibodies against cytokeratin 9 stained a high proportion of the keratinocytes in suprabasal locations. These suprabasal cytokeratin-9-positive keratinocytes were often arranged in vertical columns and concentrated around intraepid…

AdultCancer Researchmedicine.drug_classMorphogenesisFluorescent Antibody Techniquemacromolecular substancesBiologyMonoclonal antibodyBasal (phylogenetics)CytokeratinFetusmedicineAnimalsHumansMolecular BiologySkinFetusEpidermis (botany)FootCell BiologyAnatomyHandMolecular biologyCytoskeletal Proteinsmedicine.anatomical_structureEpidermal Cellsbiology.proteinKeratinsCattleAntibodyKeratinocyteNeckDevelopmental BiologyDifferentiation; research in biological diversity
researchProduct

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients…

2008

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly highe…

AdultCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentCHOPGastroenterologyDisease-Free SurvivalLymphoplasmacytic LymphomaAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedChemotherapybusiness.industryRemission InductionAntibodies MonoclonalHematologyMiddle Agedmedicine.disease3. Good healthLymphomaSurgeryTreatment OutcomeOncologyDoxorubicinVincristine030220 oncology & carcinogenesisPrednisoneRituximabWaldenstrom MacroglobulinemiaRituximabbusiness030215 immunologymedicine.drugLeukemia
researchProduct